Advertisement
On August 15, 2007, the Company submitted an application with theSecurities and Exchange Commission (SEC) to voluntarily withdraw theregistration statements filed in July relating to a proposed exchange offerinvolving holders of its currently outstanding 3.5% Subordinated Convertiblenotes due 2024 and a proposed offer to the public of an additional$30,000,000, in principal amount, of new Senior Convertible Notes due 2024.
Advertisement
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be any saleof these securities in any state or jurisdiction in which such offer,solicitation or sale would be unlawful prior to registration or qualificationunder the securities laws of any such state or jurisdiction.
About Isolagen, Inc.
Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic companycommitted to developing and commercializing scientific advances and innovativetechnologies. The company's technology platform includes the IsolagenProcess(TM), a cell processing system for skin and tissue rejuvenation whichis currently in clinical development for a broad range of aesthetic andtherapeutic applications including wrinkles, acne scars, burns and periodontaldisease. Isolagen also commercializes a scientifically-advanced line ofskincare systems through its majority-owned subsidiary, Agera(R) Laboratories,Inc. For additional information, please visit www.isolagen.com.
Isolagen Forward Looking Statements
All statements in this news release that are not based on historical factare "forward-looking statements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995 and the provisions of Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities ExchangeAct of 1934, as amended. While management has based any forward-lookingstatements contained herein on its current expectations, the information onwhich such expectations were based may change. These forward-lookingstatements rely on a number of assumptions concerning future events and aresubject to a number of risks, uncertainties, and other factors, many of whichare outside of our control, that could cause actual results to materiallydiffer from such statements. Such risks, uncertainties, and other factorsinclude, but are not necessarily limited to, those set forth under Item 1A"Risk Factors" in the Company's Annual Report on Form 10-K for the year endedDecember 31, 2006, as updated in "Item 1A. Risk Factors" in the Company'sQuarterly Reports on Form 10-Q. We operate in a highly competitive and rapidlychanging environment, thus new or unforeseen risks may arise. Accordingly,investors should not place any reliance on forward-looking statements as aprediction of actual results. We disclaim any intention to, and undertake noobligation to, update or revise any forward-looking statements. Readers arealso urged to carefully review and consider the other various disclosures inthe Company's Annual Report on Form 10-K for the year ended December 31, 2006,as well as other public filings with the SEC since such date.
SOURCE Isolagen, Inc.
